Key points from article :
Fauna Bio and Lilly partner on $494m project for preclinical drug discovery in obesity.
Fauna's AI platform, called Convergence, analyzes animal data to find human drug targets.
Lilly aims for novel obesity treatments beyond GLP-1.
Hibernation animals offer insights into metabolic control and muscle mass.
Compelling human data strengthens Fauna's platform.
" We can use this platform for multiple disease areas, particularly in cardiovascular and CNS," - Ashley Zehnder, CEO of Fauna Bio.
Fauna seeks collaborations in other disease areas like cardiovascular and CNS.
Fauna's own drug program for lung disease nears IND-enabling studies.
Animal data reveals important conserved genes for human disease targets.
